Monthly Archives: March 2020

Murchison Minerals Intersects High Grade Copper-Zinc Mineralizaton 10 Kilometres Southwest of Brabant-Mckenzie Deposit

TORONTO, ON / ACCESSWIRE / March 31, 2020 / Murchison Minerals Ltd. ("Murchison" or the "Company") (TSXV:MUR) is pleased to announce that exploration drilling on the Brabant Lake property has intersected high grade copper-zinc mineralization 10 km southwest of the Brabant-Mckenzie VMS Deposit.

The discovery is at the prospective Main Lake target, interpreted to be on the same geologic horizon as the Brabant-Mckenzie VMS Deposit. The drill hole ML-20-004 is located 270 metres northeast of the historic high grade Main Lake showing which was resampled in the summer of 2019.

The mineralization found in diamond drill hole ML-20-004 consists of a copper rich upper zone and a zinc rich lower zone. The Upper zone was intersected over an interval of 3.59 metres (139.65-143.24) with 0.83% Cu, 0.61% Zn and 11.8 g/t Ag. The Lower zone was intersected between 169.80 and 176.42 metres (6.62 metres) returning 0.09% Cu, 1.62% Zn and 41 g/t Ag over the entire interval including 1.02 metres at 5.08% Zn and 0.22 metre at 9.77% Zn. There are several high silver intercepts in this zone as well, the highest of which was 81.2 g/t Ag over 0.82 metre (169.80-170.62 metres).

"This new discovery at the Brabant project further indicates its potential to be an up and coming new VMS mining camp"- Mr. Jean-Charles Potvin, President and CEO Murchison Minerals.

Drill Hole ID

From (m)

To (m)

Length (m)

Cu (%)

Zn (%)

Ag (g/t)

Au (g/t)

ML-20-004 Upper

139.65

143.24

3.59

0.83

0.61

11.80

0.025

ML-20-004 Lower

169.80

176.42

6.62

0.09

1.62

41.10

0.056

including

169.80

170.62

0.82

0.02

0.65

81.20

0.094

including

170.62

171.64

1.02

0.15

5.08

26.90

0.081

including

176.20

176.42

0.22

0.03

9.77

56.50

0.050

Intercepts are reported as drill widths, True thickness is currently unknown

This new discovery was made following up on the anomalies identified during the 2019 airborne electromagnetic survey. This conductor is on strike with the historical high grade copper/zinc/silver at the Main Lake showing. Drill holes ML-20-001, ML-20-002 and ML-20-003 discovered weak copper and zinc mineralization but extensive VMS style alteration observed as abundant inferred anthophyllite and garnet. An offhole borehole electromagnetic anomaly was observed in hole ML-20-001 which was followed up by drilling ML-20-004 leading to the discovery. The discovery remains open in all directions and requires additional drilling. Mineralization consists of disseminated and fracture filling chalcopyrite with zinc mineralization as disseminated sphalerite and gahnite within a pyrrhotite dominant massive sulphide.

Sphalerite and Pyrrhotite mineralization in ML-20-004.

The winter 2020 drill program was originally designed to test 12 high priority drill targets but due to an unseasonably warm winter and inadequate ice conditions, the decision was made to forego drilling any targets requiring ice road access. Of the 12 targets, 5 were ultimately tested with 11 drill holes totalling 2,618 metres. Two holes were drilled at Brabant McKenzie South and significant zinc mineralization was noted in drill hole BMS-20-002 (1.49% Zn over 1.43 metres). The TOM2 and T2T targets were each tested by 1 drill hole which did not intersect any economically significant mineralization. Graphite and pyrrhotite were present in both TOM2 and T2T but do not adequately explain the strong geophysical signature and both areas require further work. The Main Lake West target was tested by 3 drill holes with copper mineralization noted in drill holes MLW-20-001, MLW-20-002 and MLW-20-003 (0.23% Cu over 6.0 metres, 0.08% Cu over 5.53 metres and 0.26% Cu over 2.03 metres, respectively). Drill results at Main Lake West are encouraging and will require future investigation.

Drill Hole ID

From (m)

To (m)

Length (m)

Cu (%)

Zn (%)

Ag (g/t)

Au (g/t)

BMS-20-002

72.62

73.04

0.42

0.06

1.49

8.37

0.032

ML-20-001

135.43

142.79

7.36

0.06

0.03

2.31

0.018

MLW-20-001

60.98

70.48

9.50

0.23

0.01

0.22

0.038

MLW-20-002

71.37

76.90

5.53

0.08

0.01

0.17

n/a

MLW-20-003

18.84

20.87

2.03

0.26

0.01

1.86

n/a

Intercepts are reported as drill widths, True thickness is currently unknown

Hole Orientation

Collar Locations

Drill Hole ID

Dip

Azimuth

Easting

Northing

Length

BMS-20-001

-50

115

580334

6220413

369.0

BMS-20-002

-50

130

580506

6220432

219.0

ML-20-001

-60

100

574754

6212447

246.0

ML-20-002

-50

100

574766

6212244

222.0

ML-20-003

-65

100

574766

6212244

204.0

ML-20-004

-72

110

574754

6212447

234.0

TM2-20-001

-60

105

575957

6215317

348.0

T2T-20-001

-60

110

577387

6215892

400.4

MLW-20-001

-50

140

574289

6212533

184.0

MLW-20-002

-50

170

574289

6212533

102.0

MLW-20-003

-60

230

574357

6212531

90.0

Total metres drilled:

2,618.4

Drill core samples were sent to the Saskatchewan Research Council (SRC) Geoanalytical Laboratories in Saskatoon for analysis. Analysis utilized SRC's Base Metal Exploration Package (ICP3) which uses an aqua regia partial digestion and analyzes for 35 elements using ICP-OES. Samples with apparent Gahnite present utilized the Multi-Element Exploration Package (ICP4) which uses a total digest and analyzes for 47 elements using ICP-OES. Gold was analyzed by Fire Assay (AU1, 15g) with an ICP-OES/AAS finish. Murchison Minerals applied industry-standard QA/QC procedures to the program. Certified reference materials, blanks and field duplicates were inserted in all drill core shipments to the laboratory.

Qualifying Statement

The foregoing scientific and technical disclosures have been reviewed by Andrew Masurat, P. Geo. and Martin St-Pierre, P. Geoph., qualified persons as defined by National Instrument 43-101. Mr. Masurat and Mr. St-Pierre are independent consultants to Murchison and the Brabant-McKenzie project.

Mineral Resource Summary for Brabant-McKenzie VMS Deposit

VerifyMe Appoints Paul Vitali to Lead New European Office

ROCHESTER, NY / ACCESSWIRE / March 31, 2020 / VerifyMe, Inc. (OTCQB:VRME), a technology solutions provider specializing in brand protection such as counterfeit prevention, authentication, serialization, track and trace features for labels, packaging and products, is pleased to announce the hiring of Paul Vitali as its Vice President of Business Development for its EMEA (Europe, Middle East, Africa) Division.

Mr. Vitali is based in Zug, Switzerland. With over 20 years of business development experience, Mr. Vitali has established relationships in the apparel, pharmaceutical and beverage industries.

VerifyMe Chief Executive Officer Patrick White, commented, Paul will assist with our on-going work with existing contacts and is expected to create new opportunities to expand VerifyMe's presence in his territories. Utilizing Paul's contacts in Europe, the Middle East and Africa at this time will allow us to explore opportunities in the EMEA market despite the current travel limitations due to the ongoing coronavirus pandemic. We look forward to working closely with Paul and the new opportunities we expect he will bring us in the EMEA."

VerifyMe VP Business Development EMEA, Paul Vitali commented, "I am extremely excited to work with VerifyMe and introduce their anti-counterfeit, authentication, serialization and track and trace security solutions to manufacturers and brand owners in the EMEA region. I will have a particular focus on apparel, pharmaceutical and beverages and believe all three industries are in need of increased security authentication. Major apparel brands need to address problems associated with sustainability, product diversion, verification of product, materials, ingredients, production, counterfeiting and customer engagement. Pharma needs authentication, anti-counterfeit, anti-diversion and track and trace capabilities. The beverage industry needs "barley to bottle" authentication. I have already identified multiple targets with a goal of attaining 10 new active clients or pilots in 2020."

About VerifyMe, Inc.

VerifyMe, Inc., is a technology solutions company that markets products supported by patents, patent applications and trade secrets which provide identifiers and serialization for authenticating, tracking and tracing functions for labels, packaging and products. The company also markets multi-factor biometric verification solutions to verify people. VerifyMe's physical technology authenticates packaging, labels and documents with a suite of proprietary security inks and pigments, which work in conjunction with serialization and track-and-trace software. The company's digital technologies authenticate people by performing strong, multi-factor biometric verification via its patented digital software platforms. To learn more, visit www.verifyme.com

Cautionary Note Regarding Forward-looking Statements

This release contains forward-looking statements regarding revenue opportunities, the use of our products in additional presses and locations, the results of ongoing tests, and roll-out of our products and authentication devices which involve uncertainty and risk. The words "believe," "may", "estimate," "continue," "anticipate," "intend," "should," "plan," "goal, " "could," "target," "potential," "is likely," "will," "expect" and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Important factors that could cause actual results to differ from those in the forward-looking statements include the Company's ability to work with partners in selling its technologies to businesses, production difficulties, our inability to enter into contracts and deals with future partners, and issues which may affect the reluctance of large companies to change their purchasing of products, acceptance of our technologies, the efficiency of our authenticators in the field, our patents including potential litigation, and the ongoing novel COVID-19 pandemic. Further information on our risk factors is contained in our filings with the SEC, including the Form 10-K for the year ended December 31, 2019. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

For Licensing or Other Information Contact:

Company: VerifyMe, Inc.
Email: IR@verifyme.com
Website: http://www.verifyme.com

EMEA Contact Details:

Paul Vitali
Zug, Switzerland
pvitali@verifyme.com
+41 76 297 5746

SOURCE: VerifyMe

ReleaseID: 583164

Werner Kitz, Leading Engineer from Siemens, Joins Exro Business Advisory Board

VANCOUVER, BC / ACCESSWIRE / March 31, 2020 / Exro Technologies Inc. (CSE:XRO);(OTCQB:EXROF) (the "Company") is pleased to announce Werner Kitz, an industry leader in electric motors and drives, has joined the Exro Business Advisory Board ("Advisory Board").

A senior executive and engineer at Siemens for more than 25 years, Mr. Kitz brings a global perspective to innovation and manufacturing in the power-conversion sector.

Mr. Kitz graduated from Rheinisch Westfälische Technische Hochschule Aachen (RWTH-Aachen) in 1981, where he focused on motors, drives and power distribution. He quickly made his mark at Siemens.

In 1982, he became an electrical engineer at Siemens' motor factory in Nuremberg, Germany. Within a year, he was promoted to Siemens' headquarters to focus on engineering and automation in the metals aspect of the industry.

In 1998, he was promoted to director of engineering for Siemens' large drives division in global markets. There he was responsible for innovation in variable speed drives for metals, O&G, test stands and new market development for high-power and high-torque applications. In 2014, he took on the role as vice-president of mill drives, in the company's minerals industry division. He retired in 2019.

"Werner has played a major role at Siemens – and the world's electrical motor and drive sector – for more than a quarter of a century," said Josh Sobil, Exro's Chief Commercial Officer. "Werner's insight, ingenuity and experience will help us accelerate the commercialization of Exro technology into the global marketplace."

"I am happy to join the Business Advisory Board to assist Josh and the Exro team in bringing Exro's technology to market," said Mr. Kitz. "Exro has the potential to add significant value to industrial sectors worldwide, ensuring we get more from the energy we use to power electric motors and powertrains."

After almost a decade of research and development, Exro is now in its commercialization phase. Sobil, along with CEO Sue Ozdemir, who was appointed Exro's CEO in September 2019 after serving as CEO of GE's Small Industrial Motors Division, are leading a strategy to introduce Exro to the automotive, energy, agricultural and recreational sectors, among others.

About Exro Technologies Inc.

Exro facilitates the transition to clean energy by providing products and services to manufacturers to increase the efficiency and reliability of power systems, including electric motors, generators and batteries. Exro's patented technology enhances energy systems by dynamically sensing and adapting variable inputs and optimally matching them to desired outputs, creating measurable performance gains and extended lifespan. The widespread applications of the technology apply to optimizing the performance of electric vehicles, UAVs, and ship drives, as well as pumps, industrial motors, and energy capture from wind and tides.

ON BEHALF OF THE BOARD OF DIRECTORS

Sue Ozdemir, Chief Executive Officer

CONTACT INFORMATION
Canada: Jake Bouma
Intrynsyc Capital Corp.
604-317-3936

United States: Vic Allgeier
TTC Group Inc.
646-841-4220
Email: info@exro.com

Forward-Looking Statements

Certain statements contained in this News Release constitute forward-looking statements. When used in this document, the words "believe", "may", "would", "could", "will" and similar expressions, as they relate to the Company or its management are intended to identify forward-looking statements. More particularly and without limitation, this news release contains forward-looking statements and information concerning the Company's intention to commercialize its product in the near term. Such statements reflect the Company's current views with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the Company's actual performance or achievements to vary from those described herein. Should one or more of these factors or uncertainties materialize, or should assumptions underlying forward-looking statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. The Company does not assume any obligation to update these forward-looking statements, except as required by law.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS NEWS RELEASE.

SOURCE: Exro Technologies Inc.

ReleaseID: 582928

Sigma Labs Launches PrintRite3D Production Series

New Production Dashboard and AI Driven Metrics Provide Critical Real-time Information as 3D Printing Alternatives Accelerate Due to Worldwide Crisis

SANTA FE, NM / ACCESSWIRE / March 31, 2020 / Sigma Labs, Inc. (NASDAQ:SGLB), a leading developer of quality assurance software for the commercial 3D printing industry, has launched Printrite3D® Production Series that introduces the ‘Production Dashboard' and provides production managers with critical metrics, insight and actionable information during the production process. This launch comes at a time when many predict that the use of 3D printing of metal parts will increase dramatically in response to COVID-19 and the effect of the pandemic on U.S. manufacturing, especially with manufacturers that rely on complex and lengthy supply chains.

3D printing is more agile and rapid in development and execution than traditional manufacturing methods and can be performed proximate to where the end product is needed, making it much more responsive in times of crisis. PrintRite3D® Production Series enhances this speed and agility by truncating the design and development process and accelerating the 3D manufacturing machine qualification and has the added advantage to remotely monitor production in real-time from anywhere in the world.

"Sigma Labs has a rich history of innovation," said Mark K. Ruport, Executive Chairman of Sigma Labs. "PrintRite3D® Production Series is the culmination of years of internal research and development and radical collaboration with our customers. We believe it will be seen as a major advancement for the additive manufacturing industry just as 3D printing of metal parts will be tested and challenged to fulfill the promise of being the next revolution in manufacturing."

Sigma's technology is unique in that it is machine agnostic and runs on most major brands of 3D metal printers. This allows for standardized quality assurance processes, even throughout a supply chain using 3D printers from different manufacturers. PrintRite3D® Production Series, which will be available in April, introduces an intuitive dashboard that provides in-process quality metrics and actionable information to production managers during the production process including:

Automated In-process Quality Metric (IPQM®) based alerts, which allow production managers to use custom metric thresholding for part and process quality decision making. In real time, the process engineer can know that the process was in control and the production manager can know the part yield predictive performance, ensuring maximum efficiency of the manufacturing process.

IPQM® trained with machine learning algorithms using micro CT-based on standard additive defects, can identify and classify known porosity modes such as, Lack of Fusion, Key Hole, Spherical Porosity and Foreign Inclusions. The process engineer can begin to qualify and certify the IPQMp as a proxy for micro CT, thereby reducing the post process measurement burden, and in real time monitor the predictive defect modes.

High resolution IPQM® "medical grade" forensic analysis in 3D for process engineering part anomaly investigation, provides a level of granularity during the build process that until now was unattainable. Using the Production Dashboard, the process engineer can begin continuous process improvement by virtue of forming a deeper understanding of the nature of 3D anomalous IPQM signature morphologies.

PrintRite3D® Production Series can be utilized remotely by production managers and operators to monitor, analyze and intervene in real time production as required from any location around the globe.

"Bringing Sigma's technology down to the manufacturing floor to be used by production managers to monitor the 3D printing process is a major step forward for the AM industry," commented Dr. Prveen Bidare, Technical Research Officer in Hybrid Manufacturing at the University of Birmingham. "PrintRite3D® Production Series addresses one of the critical barriers of the industrialization of additive manufacturing and puts highly sophisticated tools in the hands of the printer operators. Additionally, the fact that Sigma's technology can be used today on 3D printers from multiple manufacturers to provide a consistent standard of quality assurance, allows manufacturers to deploy the technology throughout their supply chain."

About Sigma Labs

Sigma Labs, Inc. (NASDAQ: SGLB) is a leading provider of quality assurance software to the commercial 3D printing industry under the PrintRite3D® brand. Founded in 2010, Sigma is a software company that specializes in the development and commercialization of real-time computer aided inspection (CAI) solutions known as PrintRite3D® for 3D advanced manufacturing technologies. Sigma Labs' advanced computer-aided software product revolutionizes commercial additive manufacturing, enabling non-destructive quality assurance mid-production, uniquely allowing errors to be corrected in real-time. For more information, please visit www.sigmalabsinc.com.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words "believe," "anticipate," "estimate," "expect," "intend," "plan," "project," "prospects," "outlook," and similar words or expressions, or future or conditional verbs such as "will," "should," "would," "may," and "could" are generally forward-looking in nature and not historical facts. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance or achievements to be materially different from any anticipated results, performance or achievements. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company's forward-looking statements, please see the Company's Annual Report on Form 10-K (including but not limited to the discussion under "Risk Factors" therein) filed with the SEC on April 1, 2019 and which may be viewed at www.sec.gov.

Contacts:

Media Contact:

Julia Wakefield
Vice President
Rubenstein Public Relations
212-805-3021
jwakefield@rubensteinpr.com
www.rubensteinpr.com

Investor Contact:

Chris Tyson
Managing Director
MZ Group – MZ North America
949-491-8235
SGLB@mzgroup.us

Company Contact:

Steven Gersten
Sigma Internal IR
investors@sigmalabsinc.com

SOURCE: Sigma Labs, Inc.

ReleaseID: 583227

AmeriCann’s Massachusetts Venture Completes First Cannabis Harvest

New Massachusetts Facility is Supplying Much Needed Medical Cannabis

DENVER, CO / ACCESSWIRE / March 31, 2020 / AmeriCann, Inc. (OTCQB:ACAN) a cannabis company that is developing state-of-the-art cultivation, processing and product manufacturing facilities, announced the first harvest at its new state-of-the-art cannabis cultivation and processing facility.

AmeriCann's Joint Venture partner recently commenced operations at AmeriCann's Massachusetts Cannabis Center ("MCC") in Freetown, MA. The initial phase of the development, Building 1, is a 30,000 square foot cultivation greenhouse and processing facility, 100 percent of which is occupied by Bask, Inc., an existing Massachusetts licensed vertically integrated cannabis operator.

Bask completed its initial cannabis harvest at Building 1 and is ramping up production to meet the growing needs in Massachusetts. Building 1 is an operating, licensed medical cannabis cultivation and processing facility, which supports Bask's medical dispensary, home delivery service, and wholesale partners.

"We are proud that we have been able to deliver this advanced, sustainable cultivation facility at this important time," stated AmeriCann CEO Tim Keogh. "Medical cannabis has been designated an essential business in Massachusetts and the initial building at our Massachusetts Cannabis Center is serving an important role in the supply chain of medicine for The Commonwealth."

Watch an updated Video on AmeriCann's Building 1

Massachusetts has implemented a "Stay at Home Advisory" in response to the COVID- 19 pandemic. Massachusetts Governor Baker deemed medical cannabis businesses as an essential service and encouraged medical cannabis businesses to continue to operate during this advisory.

To ensure business continuity and the safety of its patients and employees, AmeriCann and Bask have proactively adopted operational improvements based on guidance from the Center for Disease Control, the Cannabis Control Commission and other agencies from the Commonwealth.

During the 15-year Joint Venture for Building 1, AmeriCann will receive Base Rent and a Revenue Participation Fee from Bask of 15% of all gross monthly sales of cannabis, cannabis-infused products and non-cannabis products produced. Annually, the facility is projected to produce 7,500 pounds of dry flower cannabis and over 400,000 units of infused product.

The Massachusetts cannabis market has some of the highest cannabis prices in the United States, with wholesale prices exceeding $4,000 per pound and retail prices greater than $8,000 per pound.

The Massachusetts Cannabis Center is being developed on a 52-acre parcel located in Southeastern Massachusetts. The MCC project is permitted for 987,000 sq. ft. of cannabis cultivation and processing infrastructure, which will be developed in phases, and plans to support both the existing medical cannabis and the adult-use cannabis markets.

About AmeriCann

AmeriCann (OTCQB:ACAN) is a cannabis company that is developing cultivation, processing and product manufacturing facilities.

AmeriCann uses greenhouse technology which is superior to the current industry standard of growing cannabis in warehouse facilities under artificial lights. According to industry experts, by capturing natural sunlight, greenhouses use 25 percent fewer lights, and utility bills are up to 75 percent less than in typical warehouse cultivation facilities. As such, AmeriCann's Cannopy System enables cannabis to be produced with a greatly reduced carbon footprint, making the final product less expensive. Additionally, greenhouse construction costs are nearly half of warehouse construction costs.

AmeriCann is also designing GMP Certified cannabis extraction and product manufacturing infrastructure. Through a wholly-owned subsidiary, AmeriCann Brands, Inc., the Company intends to secure licenses to produce cannabis infused products including beverages, edibles, topicals and concentrates. AmeriCann Brands, Inc. plans to operate a Marijuana Product Manufacturing business at the Massachusetts Cannabis Center with over 40,000 square feet of state-of-the art extraction and product manufacturing infrastructure.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act") (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words "believe," "anticipate," "estimate," "expect," "intend," "plan," "project," "prospects," "outlook," and similar words or expressions, or future or conditional verbs such as "will," "should," "would," "may," and "could" are generally forward-looking in nature and not historical facts. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance or achievements to be materially different from any anticipated results, performance or achievements. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional uncertainties that could impact the Company's forward-looking statements, please see the Company's Registration Statement on Form S-1 which may be viewed at www.sec.gov.

Contact Information:

Corporate:
AmeriCann, Inc.
1550 Wewatta Street
2nd Floor
Denver, CO 80202
(303) 862-9000
info@americann.co
www.americann.co
@ACANinfo on Twitter
@AmeriCann on Facebook
@AmeriCannInc on Instagram
AmeriCann, Inc on LinkedIn

SOURCE: AmeriCann, Inc.

ReleaseID: 583291

Third Party Testing Validates Vivakor’s Kuwait Remediation Operations

Reduction in Total Hydrocarbon Contamination to 0.2% Versus Required 0.5%

LAS VEGAS, NV / ACCESSWIRE / March 31, 2020 / Vivakor, Inc. (OTC PINK:VIVK), a clean technology and asset acquisition company announces it has received third party testing results from its initial oil remediation operations in Kuwait. Results indicate that Vivakor's Remediation Processing Center Technology has reduced the Total Hydrocarbon Contamination (THC) from over 200,000 Parts Per Million (PPM) or 20% to 2100 PPM or to 0.2%. The required PPM are to be less than 5000 or 0.5%. The oil sludge remediation is part of the overall clean up of Kuwait from the Iraqi invasion some 25 years ago, and is an ongoing United Nations sanctioned clean up effort.

"We are very pleased with the results from Kuwait, as they are consistent with the results that we have forecast for this project. The pre-processed material for this set of testing was over 20% Total Hydrocarbon Contamination and our revolutionary clean technology was able to reduce that to .2%. This is an incredible achievement, and first of its kind in the region. We see a huge opportunity for the Company's technology in the Middle East North Africa (MENA) region of the world, where there are literally millions of metric tons of hydrocarbon contaminated material to be processed. Our technology has the potential to be applied to all materials where the hydrocarbon content is more than 7% and as high as 40%. This also can eliminate the need for landfills from hydrocarbon waste making the region one of the most progressive on environmental clean up in the world," stated Vivakor Chief Executive Officer Matt Nicosia.

About Vivakor, Inc.

Vivakor, Inc. (VIVK) provides clean technology solutions in remediation, waste oil to energy and critical natural resource delivery. Our focus on socially responsible technologies aim to prove profitable for investors and deliver a positive impact to the world. These holdings are proprietary and largely disruptive intellectual properties centered principally on revenue producing projects across the globe. The corporate mission is to acquire or develop distinct assets, intellectual property, and technologies that increase the value and longevity of our natural resources while improving our environment. Our primary objective is to deliver the strongest industry model while providing solid returns to our valued shareholders and partners. We carry forward lessons learned and further refine our technologies which enhances our capability to leverage assets from our projects across the globe.

For more information, please visit our website: http://vivakor.com

Forward-Looking Statements

This news release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including economic slowdown affecting companies, our ability to successfully develop products, rapid change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in Vivakor's filings with the Securities and Exchange Commission, which factors may be incorporated herein by reference. Forward-looking statements may be identified but not limited by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," or "continue" and variations or similar expressions. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.

Investors Contact:
p949-281-2606
info@vivakor.com

SOURCE: Vivakor, Inc.

ReleaseID: 583169

Odyssey Group International Provides Progress Update on its Life-Saving Medical Products

Files Quarterly Report for the Three Months Ended January 31, 2020

IRVINE, CA / ACCESSWIRE / March 31, 2020 / Odyssey Group International, Inc. (OTCQB:ODYY) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique, life-saving medical products, is pleased to provide an update on its recent business progress.

Odyssey Chairman and Chief Executive Officer Michael Redmond, commented, "With the health of our nation in focus, I am more encouraged than ever that our unique, medical products will provide clinical advantages to the market place. We are making progress on all fronts, including corporate, capital and product development. Our main goal for the remainder of 2020 is to prepare our Save a Life Choking Rescue Device and our CardioMap Device for clinical trials and regulatory submissions . We look forward to keeping our shareholders updated on our progress."

Recently achieved milestones:

December 2019 – began trading on the OTCQB

January 2020 – entered product development and design agreement for its Save a Life Choking Rescue Device with Tanaka Kapec Design Group

January 2020 – entered into a development agreement with the inventor of the current CardioMap technology to design and develop the next generation device

January 2020 – Its partner company, Prevacus, completed GMP Certification on its potential concussion drug candidate and animal safety testing on its drug for Nieman Pick's type C disease.

February 2020 – appointed Mike Contarino, experienced technical lead, as Head of Product Development to lead the medical device programs and oversee commercialization efforts.

March 2020 – signed agreement with Majic LLC, a medical device engineering firm to assist with development and product integration of CardioMap and Save a Life Choking Rescue Device

March 2020 – filed 10Q for the period ended January 31, 2020

March 2020 – raised $150,000 in convertible notes with fixed floor pricing from Accredited Investors. See our 8k filings for more on the terms of the notes

About Odyssey Group International, Inc.

Odyssey Group International, Inc. (OTCQB:ODYY) is a technology and asset acquisition company with a focus in the area of life-saving medical solutions. Odyssey's corporate mission is to create, acquire and accumulate distinct assets, intellectual properties, and exceptional technologies that provide meaningful medical solutions The Company is focused on building and acquiring assets in areas that have an identified technological advantage, provide superior clinical utility, have a substantial market opportunity and provide solid returns to its valued shareholders and partners.

For more information, visit: http://www.odysseygi.com

Forward-Looking Statements

CONTACT:

P: 619-832-2900
info@odysseygi.com

SOURCE: Odyssey Group International, Inc.

ReleaseID: 583240

ZoomAway Secures $5M Acquisition Line of Credit

VANCOUVER, BC / ACCESSWIRE / March 31, 2020 / ZoomAway Travel Inc. (TSX.V:ZMA);(OTCQB:ZMWYF) (the "Company" or "ZMA") www.zoomaway.com, a leader in the hospitality technology sector, is pleased to announce that it has secured a $5M acquisition credit line (the "Acquisition Credit Line") from Toronto based AIP Asset Management ("AIP").

Funds would only be provided by AIP upon its review of any potential acquisition for which such funds would be utilized. Any potential material acquisition would also be subject to approval by the TSX Venture Exchange.

Interest on advances under the Acquisition Credit Line are set at 6% per annum, compounded monthly, and there will be a closing fee equal to 1% of proceeds payable when each tranche is advanced.

Sean Schaeffer, CEO of Zoomaway Travel, commented, "I am excited to receive this ongoing commitment from AIP. To be able to find growth capital in this turbulent time is a real credit to our business and plan for growth. We are actively looking at several opportunities that have great revenues and fit our overall business model. This credit facility brings us one step closer to seeing our strategy come to fruition.

This loan facility is also subject to Exchange review and approval.

For additional information contact: Sean Schaeffer, President, ZoomAway Inc., at 775-691-8860 | sean@zoomaway.com or stay up-to-date and sign up for our newsletter.

About Us

ZoomAway, Inc. (Nevada Co.) Zoomaway Travel Inc. is a technology company that is revolutionizing the Hospitality and Travel Industries. We have developed a variety of software solutions that enhance the planning and engagement of everyday tourists. Our flagship project, ZoomedOUT, is a complete modernization and re-imagination of mobile travel apps. In a full 3D environment, we are able to integrate planning, booking, social media, and camaraderie into a tangibly rewarding experience. We are combining Travel, Hospitality, Mobile Gaming and Augmented Reality to change the way users travel into 2020 and beyond. Additional information about ZoomAway Inc. can be found at www.zoomaway.com.

ZMA Travel Game Inc. (Canadian Co.) (formerly TravelGameBlockChain Technology Inc.) is a ZoomAway Travel Inc. subsidiary company dedicated to housing new projects in the digital games. The company's first project is ZoomedOUT which can be seen at zoomedout.io. To receive more detailed, or investor level information, please contact us at sean@zoomaway.com and we will respond with the appropriate documentation depending on your request.

About Zero8 Studios, Inc.

Zero8 Studios, based in Reno, Nevada, specializes in new and innovative games and technology platforms. With a focus on social gaming and almost two decades of experience building
countless game titles, gaming platforms, and various technologies. The Zero8 Studios' team has assisted dozens of AAA publishers, large clientele, manufacturers, and casinos in the design, production, and delivery of their products to players around the world. Additional information can be found at www.zero8studios.com.

Forward-Looking Statements

This release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates, and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.

Neither the TSX Venture Exchange nor it's Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. The TSX Venture Exchange Inc. has in no way passed upon the merits of the proposed Offering and has neither approved nor disapproved the contents of this press release.

SOURCE: ZoomAway Travel Inc.

ReleaseID: 583225

Cipherloc Announces Corporate Restructuring

ARLINGTON, VA / ACCESSWIRE / March 31, 2020 / Today Cipherloc Corporation (OTCQB:CLOK) (the "Company"), a developer of advanced encryption technology, announced plans to restructure its corporate operations. As part of the restructuring, the company will reduce staff and focus on completion of testing necessary to bring its polymorphic encryption solutions to market. As part of the restructuring, Chief Executive Officer Andrew Borene will step down and Milton Mattox, Chief Operating Officer, will become the principal officer for oversight of the company's ongoing operations.

The unprecedented changes sweeping the business landscape and financial markets as a result of the COVID-19 pandemic require Cipherloc to rapidly and aggressively adapt its strategy for the months ahead. These changes will include a reduction in headcount to focus on engineering and development roles needed to guide its technology through the current phase of critical testing in order to be market ready for customer and partners who can do business with Cipherloc. In doing so, the Company will reduce its operating costs while advancing the critical steps needed to make its technologies available to the market.

Cipherloc believes its patented Polymorphic Key Progression Algorithm (PKPA) and advanced encryption solutions can enhance standard encryption through the process of polymorphism. Data is broken up into fragments, each encrypted with its own unique cipher and key pair. Unlike traditional encryption, this creates multiple pairs of ciphers and keys that can be processed in parallel, rather than a single block of data encrypted with a single key.

The Company expects to continue its focus on delivering solutions tailored to encryption and data security needs not just for today, but also for the rapidly approaching quantum computing era. The Company believes its advanced encryption technologies can reduce latency, decrease energy consumption and enable a platform or network to dynamically adapt to future encryption standards that will become the standard in protecting the most valuable data assets in both government and commercial organizations from ever more advanced cyberthreats. The Company's focus will be on critical testing and certifications needed to document its technologies and make them sale ready to an array of potential customers.

About Cipherloc Corporation (OTCQB: CLOK)

Cipherloc Corporation provides advanced technology and expertise to secure your data and safeguard your privacy with the speed you need today and the agility you'll need tomorrow. Our patented polymorphic encryption technology provides a layer of security that is stronger, adaptable, and scalable across a variety of applications and systems. Learn more at www.quantanova.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the Company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set forth in the Company's SEC filings. These risks and uncertainties could cause the Company's actual results to differ materially from those indicated in the forward-looking statements.

Cipherloc Investor Contact:

Matt Kreps
Darrow Associates, Investor Relations
214-597-8200
mkreps@darrowir.com

SOURCE: CipherLoc Corporation

ReleaseID: 583208

GT Biopharma Announces Commencement of Retreatment of Patient Demonstrating Successful Clinical Benefit following GTB-3550 TriKE(TM) therapy

Patient Achieved Stable Disease

BEVERLY HILLS, CA / ACCESSWIRE / March 31, 2020 / GT Biopharma, Inc. (OTCQB:GTBP);(GTBP.PA) a company focused on developing innovative therapeutic treatments based on its proprietary NK cell engager TriKE™ platform announced today that it has been given approval and started retreatment on Monday March 30, 2020 of the first patient to receive the lowest dose of GTB-3550 in its GTB-3550 Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML).

Following initial treatment, the patient achieved stable disease with respect to the number of AML blasts observed in their bone marrow before and after and showed no adverse events (side effects). Additionally, we observed an increase in the patient's total NK cell population attributable to the IL-15 component of the TriKE™ molecule with no appreciable increase of any hyper-active T-cell population which could have resulted in cytokine storm or other T-cell associated toxicities. The first advanced AML cancer patient enrolled in the clinical trial was treated at a dose of 5µg/kg/day GTB-3550 which is the lowest dose administered to patients enrolled in the GTB-3550 clinical trial.

GTB-3550 is a tri-specific recombinant fusion protein conjugate composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15. The NK cell-stimulating cytokine human IL-15 portion of the molecule provides a self-sustaining signal that activates NK cells and enhances their ability to kill. GTB-3550, unlike therapy with CAR T-cells, does not involve expensive adoptive cell therapy protocols.

Acute myeloid leukemia is a heterogeneous hematologic stem cell malignancy in adults with an incidence rate of 3% to 5% per 100,000 people. The median age at the time of diagnosis is 65 to 69 years. AML is an aggressive cancer that is fatal without treatment. The five-year overall survival rate for AML is 27.4 percent, according to the National Cancer Institute (NCI).

Mr. Anthony Cataldo, the Chairman and Chief Executive Officer of GT Biopharma commented: "we are pleased to commence retreatment of the initial patient, and look forward to continuing enrollment of new patients entering the clinical trial as our pause to free hospital beds for potential coronavirus patients abates." Mr. Cataldo further commented, "we remain optimistic that GTB-3550 will continue to demonstrate therapeutic benefit in AML cancer patients with advanced disease." Mr. Cataldo added, "We believe our AML TriKE™ will provide much better economics to the patients and our company then CAR T-cell therapies (Celegen and Gilead Sciences) that involve expensive adoptive cell therapy protocols.

The robustness of the TriKE™ platform allows us to develop therapeutics for the treatment of other cancers and certain infectious diseases including HIV and coronavirus infections. We most recently announced our Coronavirus TriKE™ partnership with USA-based manufacturing company Cytovance Biologics (a division of multi-billion dollar Shenzhen Hepalink Pharmaceutical Group of companies (002399:CH Shenzhen, CHINA). We are excited by the progress of our TriKE™ platform and will continue to update our shareholders as the Coronavirus TriKE™ and GTB-3550 TriKe™ continue to progress."

About GT Biopharma, Inc.

GT Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of immuno-oncology and infectious disease therapeutic products based our proprietary Tri-specific Killer Engager (TriKE™) platform. Our TriKE platform is designed to harness and enhance the cancer cell and virus-infected cell killing using the patient's immune system natural killer cells (NK cells). GT Biopharma has an exclusive worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using proprietary TriKE technology developed by researchers at the university to target NK cells.

Forward-Looking Statements

This press release contains certain forward-looking statements that involve risks, uncertainties and assumptions that are difficult to predict, including statements regarding the potential acquisition, the likelihood of closing the potential transaction, our clinical focus, and our current and proposed trials. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as "believes", "hopes", "intends", "estimates", "expects", "projects", "plans", "anticipates" and variations thereof, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. Our forward-looking statements are not a guarantee of performance, and actual results could differ materially from those contained in or expressed by such statements. In evaluating all such statements, we urge you to specifically consider the various risk factors identified in our Form 10-K for the fiscal year ended December 31, 2018 in the section titled "Risk Factors" in Part I, Item 1A and in our subsequent filings with the Securities and Exchange Commission, any of which could cause actual results to differ materially from those indicated by our forward-looking statements.

Our forward-looking statements reflect our current views with respect to future events and are based on currently available financial, economic, scientific, and competitive data and information on current business plans. You should not place undue reliance on our forward-looking statements, which are subject to risks and uncertainties relating to, among other things: (i) the sufficiency of our cash position and our ongoing ability to raise additional capital to fund our operations, (ii) our ability to complete our contemplated clinical trials for any of our drug product candidates, or to meet the FDA's requirements with respect to safety and efficacy, (iii) our ability to identify patients to enroll in our clinical trials in a timely fashion, (iv) our ability to achieve approval of a marketable product, (v) design, implementation and conduct of clinical trials, (vii) the results of our clinical trials, including the possibility of unfavorable clinical trial results, (vii) the market for, and marketability of, any product that is approved, (viii) the existence or development of treatments that are viewed by medical professionals or patients as superior to our products, (ix) regulatory initiatives, compliance with governmental regulations and the regulatory approval process, and social conditions, and (x) various other matters, many of which are beyond our control. Should one or more of these risks or uncertainties develop, or should underlying assumptions prove to be incorrect, actual results may vary materially and adversely from those anticipated, believed, estimated, or otherwise indicated by our forward-looking statements.

We intend that all forward-looking statements made in this press release will be subject to the safe harbor protection of the federal securities laws pursuant to Section 27A of the Securities Act, to the extent applicable. Except as required by law, we do not undertake any responsibility to update these forward-looking statements to take into account events or circumstances that occur after the date of this press release. Additionally, we do not undertake any responsibility to update you on the occurrence of any unanticipated events which may cause actual results to differ from those expressed or implied by these forward-looking statements.

For more information, please visit www.gtbiopharma.com.

SOURCE: GT Biopharma, Inc.

ReleaseID: 583212